Practical considerations in the pharmacological treatment of postherpetic neuralgia for the primary care provider

Journal of Pain Research

Volumn 7, Issue , 2014, Pages 125-132

  Massengill, Jamie S ^a   Kittredge, John L ^b  

^a JSM Medical   (United States)

^b Michiana Spine Sports and Occupational Rehab   (United States)

Author keywords

Clinical practice; Herpes zoster; Pharmacological treatment; Postherpetic neuralgia; Practical guidelines; Primary care

Indexed keywords

ACICLOVIR; AMITRIPTYLINE; ANALGESIC AGENT; ANTIVIRUS AGENT; CAPSAICIN; CHICKENPOX VACCINE; CORTICOSTEROID; DESIPRAMINE; FAMCICLOVIR; GABAPENTIN; GABAPENTIN ENACARBIL; LIDOCAINE; LONG ACTING DRUG; METHADONE; MORPHINE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PREGABALIN; SHORT ACTING DRUG; TOPICAL AGENT; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; VALACICLOVIR; VARICELLA ZOSTER VACCINE;

ADVERSE OUTCOME; ANALGESIA; ANOREXIA; ANTIVIRAL THERAPY; ANXIETY DISORDER; APPLICATION SITE BURNING; APPLICATION SITE ERYTHEMA; APPLICATION SITE PAIN; APPLICATION SITE PAPULE; APPLICATION SITE PRURITUS; BALANCE IMPAIRMENT; BLURRED VISION; CARDIOTOXICITY; CHICKENPOX; CLINICAL ASSESSMENT; CLINICAL PRACTICE; COGNITIVE DEFECT; COMORBIDITY; CONFUSION; CONSTIPATION; DEPENDENT PERSONALITY DISORDER; DERMATOME; DIARRHEA; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFICACY; GENERAL PRACTITIONER; GERIATRIC PATIENT; HEALTH CARE AVAILABILITY; HEART ARRHYTHMIA; HEART BLOCK; HEART INFARCTION; HERPES ZOSTER; HIP FRACTURE; HUMAN; IMMUNIZATION; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; NAUSEA AND VOMITING; NEUROPATHIC PAIN; PATIENT CARE; PATIENT PREFERENCE; PERIPHERAL EDEMA; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; POLYPHARMACY; POSTHERPETIC NEURALGIA; PRIMARY MEDICAL CARE; QUALITY OF LIFE; REVIEW; SEIZURE; SOMNOLENCE; SUICIDAL IDEATION; SWELLING; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; URINE RETENTION; VIRUS REPLICATION; VULNERABLE POPULATION; XEROSTOMIA;

EID: 84897839709     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/jpr.s57242     Document Type: Review

References (66)

1. Watson P. Postherpetic neuralgia. Am Fam Physician. 2011;84(6): 690-692.
2. Tontodonati M, Ursini T, Polilli E, et al. Post-herpetic neuralgia. Int J Gen Med. 2012;5:861-871.
3. Harpaz R, Nagel MA, Schmader K, Tyring SK, Yawn BP. Roundtable on postherpetic neuralgia - what, why, how long, and what's next? Popul Health Manag. 2012;15(6):385-390.
4. Frisch S, Guo AM. Diagnostic methods and management strategies of herpes simplex and herpes zoster infections. Clin Geriatr Med. 2013;29(2):501-526.
5. Centers for Disease Control and Prevention. Shingles (herpes zoster). 2011. Available from: http://www.cdc.gov/shingles/about. Accessed January 15, 2014.
6. Reda H, Greene K, Rice FL, Rowbotham MC, Petersen KL. Natural history of herpes zoster: late follow-up of 3.9 years (n=43) and 7.7 years (n=10). Pain. 2013;154(10):2227-2233.
7. Baron R. Mechanisms of postherpetic neuralgia - we are hot on the scent. Pain. 2008;140(3):395-396.
8. Pickering G, Leplege A. Herpes zoster pain, postherpetic neuralgia, and quality of life in the elderly. Pain Pract. 2011;11(4):397-402.
9. Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656-666.
10. Weaver BA. Herpes zoster overview: natural history and incidence. J Am Osteopath Assoc. 2009;109 Suppl 2:S2-S6.
11. Jung BF, Johnson RW, Griffn DR, Dworkin RH. Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology. 2004;62(9):1545-1551.
12. Opstelten W, Zuithoff NP, van Essen GA, et al. Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain. 2007;132 Suppl 1:S52-S59.
13. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet. 2009;374(9696):1196-1208.
14. US Census Bureau. National population projection summary tables. 2012. Available from: http://www.census.gov/prod/2011pubs/12statab/pop.pdf. Accessed January 15, 2014.
15. Bennett GJ, Watson CP. Herpes zoster and postherpetic neuralgia: past, present and future. Pain Res Manag. 2009;14(4):275-282.
16. Johnson RW. Herpes zoster and postherpetic neuralgia: a review of the effects of vaccination. Aging Clin Exp Res. 2009;21(3):236-243.
17. Gan EY, Tian EA, Tey HL. Management of herpes zoster and post-herpetic neuralgia. Am J Clin Dermatol. 2013;14(2):77-85.
18. Harden RN, Kaye AD, Kintanar T, Argoff CE. Evidence-based guidance for the management of postherpetic neuralgia in primary care. Postgrad Med. 2013;125(4):191-202.
19. Goldman GS, King PG. Review of the United States universal varicella vaccination program: herpes zoster incidence rates, cost-effectiveness, and vaccine effcacy based primarily on the Antelope Valley Varicella Active Surveillance Project data. Vaccine. 2013;31(13):1680-1694.
20. Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5):1177-1184.
21. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795-2800.
22. Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83(12):1432-1437.
23. Thakur R, Philip AG. Chronic pain perspectives: treating herpes zoster and postherpetic neuralgia: an evidence-based approach. J Fam Pract. 2012;61 Suppl 9:S9-S15.
24. Saks GM. Unmet need in the treatment of postherpetic neuralgia. Am J Manag Care. 2013;19 Suppl 1:S207-S213.
25. Klompas M, Kulldorff M, Vilk Y, Bialek SR, Harpaz R. Herpes zoster and postherpetic neuralgia surveillance using structured electronic data. Mayo Clin Proc. 2011;86(12):1146-1153.
26. Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia: an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurolog y. 2004;63(6):959-965.
27. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85 (Suppl 3):S3-S14.
28. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e88.
29. Rastogi R, Meek BD. Management of chronic pain in elderly, frail patients: fnding a suitable, personalized method of control. Clin Interv Aging. 2013;8:37-46.
30. Abdulla A, Adams N, Bone M, et al. Guidance on the management of pain in older people. Age Ageing. 2013;42 Suppl 1:i1-i57.
31. Glauser TA, Salinas GD, Nevins H, Williamson JC, Wallace MS, Abdolrasulnia M. Communication gaps between physicians and patients with postherpetic neuralgia: results from a national study on practice patterns. J Pain Res. 2011;4:407-415.
32. Dworkin RH, Panarites CJ, Armstrong E P, Malone DC, Pham S V. Is treatment of postherpetic neuralgia in the community consistent with evidence-based recommendations? Pain. 2012;153(4):869-875.
33. Dworkin RH, Schmader KE. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis. 2003;36(7):877-882.
34. Pickering G, Pereira B, Clere F, et al. Cognitive function in older patients with postherpetic neuralgia. Pain Pract. Epub May 23, 2013.
35. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60(4):616-631.
36. Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D. Adverse effects associated with non-opioid and opi-oid treatment in patients with chronic pain. Clin Drug Investig. 2012;32 Suppl 1:53-63.
37. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113-130.
38. Merck. Varivax [prescribing information]. 2013. Available from: http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax_pi.pdf. Accessed January 15, 2014.
39. Merck. Zostavax [prescribing information]. 2006. Available from: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed January 15, 2014.
40. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
41. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG. Vaccines for preventing herpes zoster in older adults. Cochrane Database Syst Rev. 2012;10:CD008858.
42. Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the effcacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis. 2012;55(10):1320-1328.
43. Cohen EJ. Prevention of herpes zoster: we need to do better. JAMA Ophthalmol. 2013;131(3):396-398.
44. Javed S, Javed F, Mays RM, Tyring SK. Herpes zoster vaccine awareness among people $50 years of age and its implications on immunization. Dermatol Online J. 2012;18(8):2.
45. Bruxelle J, Pinchinat S. Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: review of international publications. Med Mal Infect. 2012;42(2):53-58.
46. GlaxoSmithKline Australia. Zovirax [prescribing information]. 2013. Available from: http://www.gsk.com.au/products_prescription-medicines_detail.aspx?view=153. Accessed February 6, 2014.
47. Novartis. Famvir [prescribing information]. 2013. Available from: http://www.pharma.us.novartis.com/product/pi/pdf/Famvir.pdf. Accessed February 3, 2014.
48. GlaxoSmithKline. Valtrex [prescribing information]. 2013. Available from: http://us.gsk.com/products/assets/us_valtrex.pdf. Accessed January 15, 2014.
49. Wood MJ, Shukla S, Fiddian A P, Crooks RJ. Treatment of acute herpes zoster: effect of early (,48 h) versus late (48-72 h) therapy with acyclovir and valaciclovir on prolonged pain. J Infect Dis. 1998; 178 Suppl 1:S81-S84.
50. Lapolla W, Digiorgio C, Haitz K, et al. Incidence of postherpetic neuralgia after combination treatment with gabapentin and valacyclovir in patients with acute herpes zoster: open-label study. Arch Dermatol. 2011;147(8):901-907.
51. Han Y, Zhang J, Chen N, He L, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2013;3:CD005582.
52. Pfzer. Neurontin [prescribing information]. 2012. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=630. Accessed January 15, 2014.
53. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25(1):81-104.
54. Johnson P, Becker L, Halpern R, Sweeney M. Real-world treatment of post-herpetic neuralgia with gabapentin or pregabalin. Clin Drug Investig. 2013;33(1):35-44.
55. Depomed. Gralise [prescribing information]. 2012. Available from: http://www.gralise.com/lib/PDFS/GRALISE_PI.pdf. Accessed January 15, 2014.
56. XenoPort. Horizant [prescribing information]. Available from: http://www.horizant.com/docs/Horizant_PrescribingInformation.pdf. Accessed January 15, 2014.
57. Irving GA, Sweeney M. Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia. J Pain Res. 2012;5:203-208.
58. Zhang L, Rainka M, Freeman R, et al. A randomized, double-blind, placebo-controlled trial to assess the effcacy and safety of gabapentin enacarbil in subjects with neuropathic pain associated with postherpetic neuralgia (PXN110748). J Pain. 2013;14(6):590-603.
59. Pfizer. Lyrica [prescribing information]. 2013. Available from: http://labeling.pfizer.com/ShowLabeling.aspx?id=561. Accessed January 15, 2014.
60. Endo. Lidoderm [prescribing information]. Available from: http://www.endo.com/File%20Library/Products/Prescribing%20Information/LIDODERM_prescribing_information.html. Accessed January 15, 2014.
61. Acorda Therapeutics. Qutenza [prescribing information]. Available from: http://www.qutenza.com/_docs/qutenza_full_PI_.pdf. Accessed January 15, 2014.
62. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain: a Cochrane review. J Neurol Neurosurg Psychiatry. 2010;81(12):1372-1373.
63. Watson C P, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology. 1998;51(4):1166-1171.
64. Watson C P, Tyler KL, Bickers DR, Millikan LE, Smith S, Coleman E. A randomized vehicle-controlled trial of topical capsaicin in the treatment of postherpetic neuralgia. Clin Ther. 1993;15(3):510-526.
65. Stempniak M. Closing the primary care gap. Hosp Health Netw. 2013;87(3):45-52.
66. Wolff K, Johnson R, Fitzpatrick TB. Fitpatrick's color atlas and synopsis of clinical dermatology. 5th Ed. New York; McGraw-Hill Education; 2005.